Evidence map›Paper›PMID 35361959›Full record

ArticleCancer gene therapy2022

Correction: PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3.

Zhipeng Gao, Xiaojun Man, Zhenhua Li, Jianbin Bi, Xiankui Liu, Zeliang Li, Jun Li, Zhe Zhang, Chuize Kong

Open access · bronzeAbstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhipeng GaoDepartment of Urology, First Hospital of China Medical University, 155 North Nanjing Street, Heping, 110001, Shenyang, Liaoning, China.
Xiaojun ManDepartment of Urology, First Hospital of China Medical University, 155 North Nanjing Street, Heping, 110001, Shenyang, Liaoning, China.
Zhenhua LiDepartment of Urology, First Hospital of China Medical University, 155 North Nanjing Street, Heping, 110001, Shenyang, Liaoning, China.
Jianbin BiDepartment of Urology, First Hospital of China Medical University, 155 North Nanjing Street, Heping, 110001, Shenyang, Liaoning, China.
Xiankui LiuDepartment of Urology, First Hospital of China Medical University, 155 North Nanjing Street, Heping, 110001, Shenyang, Liaoning, China.
Zeliang LiDepartment of Urology, First Hospital of China Medical University, 155 North Nanjing Street, Heping, 110001, Shenyang, Liaoning, China.
Jun LiDepartment of Urology, First Hospital of China Medical University, 155 North Nanjing Street, Heping, 110001, Shenyang, Liaoning, China.
Zhe ZhangDepartment of Urology, First Hospital of China Medical University, 155 North Nanjing Street, Heping, 110001, Shenyang, Liaoning, China. zhezhangcmu@qq.com.
Chuize KongDepartment of Urology, First Hospital of China Medical University, 155 North Nanjing Street, Heping, 110001, Shenyang, Liaoning, China. kongchuize_cmu@sina.cn.
China Medical University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35361959
OpenAlexW4220795661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.